Gambogic acid suppresses hypoxia-induced hypoxia-inducible factor-1α/vascular endothelial growth factor expression via inhibiting phosphatidylinositol 3-kinase/Akt/mammalian target protein of rapamycin pathway in multiple myeloma cells

Fei Wang,1 Wei Zhang,2 Liting Guo,1 Wen Bao,1 Nan Jin,1 Ran Liu,1 Ping Liu,1 Yonghui Wang,2 Qinglong Guo4 and Baoan Chen1

1Department of Hematology and Oncology (Key Department of Jiangsu Medicine), Medical School, Zhongda Hospital, Southeast University, Nanjing; 2Department of Pathology, Medical School, Southeast University, Nanjing; 3Department of General Surgery, Medical School, Zhongda Hospital, Southeast University, Nanjing; 4State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, Nanjing, China

Key words
Angiogenesis, gambogic acid, hypoxia-inducible factor 1 alpha subunit, multiple myeloma, vascular endothelial growth factor A

Correspondence  Baoan Chen, Department of Hematology and Oncology (Key Department of Jiangsu Medicine), The Affiliated Zhongda Hospital, Medical School, Southeast University, 87 Dingjiaqiao, Nanjing 210009, China. Tel: 86-25-8327-2006; Fax +86-25-8327-2011; E-mail: cbab8888@hotmail.com

Received March 18, 2014; Revised May 26, 2014; Accepted May 27, 2014

Cancer Sci 105 (2014) 1063–1070
doi: 10.1111/cas.12458

In multiple myeloma (MM), the hypoxic environment is an important factor causing tumor angiogenesis, which is strongly correlated to disease progression and unfavorable outcome by activating the key transcription factor, hypoxia-inducible factor-1α (HIF-1α). Gambogic acid (GA) is the major active ingredient of gamboge, which has been shown to possess antitumor effect by in vitro and in vivo study. However, the underlying molecular mechanism of whether GA inhibits tumor angiogenesis remains poorly understood. In this study, we investigated the effects of GA on expression of HIF-1α, and its downstream target gene vascular endothelial growth factor (VEGF) in human MM U266 cells. We found that hypoxia induced increase in the level of HIF-1α subunit protein and activated the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target protein of rapamycin (mTOR) pathway. Moreover, the treatment with GA markedly decreased HIF-1α and VEGF expression under hypoxic conditions. Mechanistic studies exhibited that GA inhibited the production of HIF-1α by reducing phosphorylation of Akt and mTOR in U266 cells. Furthermore, in vivo study revealed that intravenous injection of GA once every other day for 2 weeks could suppress tumor volumes by antiangiogenesis activity. Taken together, our results identify that GA suppresses hypoxia-activated pathways that are linked to MM progression, at least partly, by the inhibition of the PI3K/Akt/mTOR signaling pathway. Therefore, GA may be a new potent therapeutic agent against human MM cells.

Multiple myeloma (MM) is the second most common (10–15% of all) hematological cancers characterized by the accumulation of malignant plasma cells within the bone marrow. It is responsible for 15–20% of deaths from hematological cancer and about 2% of all deaths from cancer. Angiogenesis, supporting the growth and survival of plasma cells, plays a critical role in the pathophysiology and progression of MM. Hypoxia, a key feature of the tumor microenvironment, has been shown to be a leading cause of angiogenesis. In the tumor cells, hypoxia-inducible factor-1α (HIF-1α) has been regarded as the most important transcriptional factor promoting angiogenesis by upregulating pro-angiogenic genes such as vascular endothelial growth factor (VEGF), which can enhance the microvascular density of bone marrow and accounts for the abnormal structure of myeloma tumor vessels.

Under hypoxia, HIF-1α can escape the Von Hippel-Lindau tumor suppressor protein (VHL) binding and protosomal degradation, translocate to the nucleus, heterodimerize with HIF-1β, and induce transcription of numerous target genes related to cell migration, vascular remodeling and angiogenesis for adaptation to hypoxia. Increased HIF-1α levels are also associated with increased risk of mortality in many human cancers. The previous studies have demonstrated the bone marrow microenvironment is hypoxic in MM patients and determined the role of hypoxia in progression and dissemination of MM mouse models. These findings suggest HIF-1α could be a potential therapeutic target.

Recent studies have shown many mechanisms regulate the HIF-1α expression at the level of transcription, translation and protein stability, such as nuclear factor-κ B (NF-κB), phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathways, and prolyl hydroxylase (PHD)-pVHL-dependent mechanisms. Among these mechanisms, PI3K/AKT pathway is an important element in response to hypoxia. Hypoxia can stimulate the activation of PI3K/Akt pathway. It has become
increasingly evident that the increase of HIF-1α synthesis is associated with activated PI3K/Akt signaling that stimulates mammalian target protein of rapamycin (mTOR) activity, result in augmenting translation of HIF-1α mRNA into protein. The suppression of PI3K and mTOR can inhibit HIF-1α expression in non-hypoxic and hypoxic cells. Therefore, pharmacological inhibition of HIF-1α activity may represent a useful treatment strategy.17,18

Gambogic acid (GA), a main active ingredient of gamboge, is a brownish to orange dry resin secreted from Garcinia hanburyi, which is a plant distributed widely in nature (Fig. 1). Recently, in vitro and in vivo studies have demonstrated that GA exerts potent anti-tumor effects on solid tumors and hematological malignancies.19 In addition, GA can inhibit angiogenesis through suppressing secretion of VEGF.20

However, whether GA has an ability to suppress HIF-1α/VEGF expression via inhibition of PI3K/Akt/mTOR signaling pathway under hypoxia in human multiple myeloma cells still remains unclear. Thus, in our study, we investigated the effect of GA on HIF-1α/VEGF induction under hypoxia in human myeloma cell line, U266, and its underlying molecular mechanism.

Materials and Methods

Cell culture and induction of hypoxia. The human myeloma cell line, U266 was obtained from Shanghai Cell Bank of Chinese Academy of Sciences (Shanghai, China). The cells were maintained in RPMI-1640 medium (Gibco, Grand Island, NY, USA) supplemented with 15% heat-inactivated fetal bovine serum (Sijiqing, Hangzhou, China), 100 U/mL penicillin and 100 μg/mL streptomycin (Sigma-Aldrich, St. Louis, MO, USA) in a humidified atmosphere of 5% CO2 at 37°C. For hypoxia induction, cells were incubated in a sealed hypoxic chamber flushed with a gas mixture of 94% N2, 5% CO2 and 1% O2.

Cytotoxicity assay. Gambogic acid (Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, China) was dissolved in DMSO (Sigma-Aldrich), stored at −20°C, and diluted as needed in RPMI-1640. Cytotoxic effect of GA on proliferating cells was assayed by CCK8 (Dojindo, Kumamoto, Japan). Briefly, cells were seeded onto 96-well plates at a density of 3 × 10^4 cells/well and treated with various concentrations of GA for 8 h. Then CCK-8 solution (10 μL) was added to each well and incubated for 3 h. The absorbance was measured at 450 nm by Multiskan MK3 (Thermo Scientific, Shanghai, China). Cell viability was calculated as a percentage of viable cells in the GA-treated group versus the untreated control.

Quantitative real-time PCR assay. Total RNA was isolated from cells by using RNAiso Plus (TaKaRa, Dalian, China). Reverse transcription was performed with PrimeScript RT reagent kit with gDNA Eraser (TaKaRa), and real time PCR was carried out using SYBR Premix Ex Taq (TaKaRa). The real time PCR reaction contained: 10 μL of SYBR Premix Ex Taq, 0.4 μL of forward primer, 0.4 μL of reverse primer, 0.4 μL ROX Reference Dye, 1 μL of cDNA template, and 7.8 μL of dH2O. The program was 95°C for 30 s, followed by 40 cycles of 95°C for 30 s, 60°C for 30 s, and 72°C for 30 s. The relative expression level of mRNAs was normalized to that of internal control β-actin using the 2^(-ΔΔCt) threshold method. The primer sequences were as follows:

VEGFA (forward) 5’-GAGCCCTTGCTTGTGCTCTAC-3’; VEGFA (reverse) 5’-CACCAGGTTCTGATTGGATG-3’; HIF-1α (forward) 5’-TGAGAAATGAGAATGCTTACA-3’; HIF-1α (reverse) 5’-ACACTGAGGTTGGTTACTGGTG-3’; β-actin (forward) 5’-AAAGACCTGTACGCCAACAC-3’; β-actin (reverse) 5’-GTCTACTCTTGTCTGTGAT-3’.

ELISA. 3 × 10^5 cells were seeded onto 6-well plates in serum-free medium containing various concentrations of GA (0, 0.05, 0.1 and 0.2 μM) and incubated for 8 h at hypoxia or normoxia. The conditioned medium was collected, and VEGF levels were determined by VEGF ELISA kit (Neobioscience, Shenzhen, China) according to the manufacturer’s protocols. VEGF was expressed as a picogram of VEGF protein per milliliter medium and per 10^5 cells.

Immunofluorescent staining. Cells were dripped on glass slides and fixed with 4% paraformaldehyde for 30 min at room temperature, treated with 0.2% Triton X-100 and blocking solution (5% BSA and 0.2% Triton X-100 in PBS) for 30 min, respectively. The cells were incubated with mouse anti-human HIF-1α (1:50, Santa Cruz Biotechnology, Santa Cruz, CA, USA) overnight at 4°C and then incubated with FITC-conjugated goat anti-mouse IgG (1:100, Santa Cruz Biotechnology) for 2 h at room temperature. Then the cell nucleus was stained with DAPI (Beyotime, Haimen, China) for 5 min. Between each step, the cells were washed with PBS three times. The results of staining were photographed with a fluorescence confocal microscope (FV-1000, Olympus, Tokyo, Japan).

Western blot analysis. Rapamycin and LY294002 were purchased from Sigma. Protein extraction from cells and western blot analysis were performed as described previously.21 Blots
were incubated respectively with various appropriately diluted primary antibodies for HIF-1α and VEGF (Santa Cruz Biotechnology), Akt, phospho-Akt, mTOR and phospho-mTOR (Cell Signaling, Beverly, MA, USA) overnight at 4°C, and then followed by horseradish peroxidase-conjugated goat anti-rabbit or mouse secondary antibody (Santa Cruz Biotechnology) for 2 h at room temperature. The β-actin (Santa Cruz Biotechnology) was used as the internal control. For quantity, images were analyzed using Image J software from the NIH (Bethesda, MD, USA).

Mouse xenograft model. Six-week-old male BALB/c nude mice, with body weights of 18–22 g, were procured from Shanghai National Center for Laboratory Animals (Shanghai, China) and maintained in a specific pathogen-free environment. Studies were performed in adherence with the Guidelines established by the National Science Council, Republic of China. The mice were subcutaneously injected with $1 \times 10^7$ cells. Tumor volume was measured every other day with caliper and calculated according to the formula: $V = a^2b/2$, where $a$ is the smallest superficial diameter and $b$ is the largest superficial diameter. When the tumor volume reached approximately 50 mm$^3$, the mice ($n = 6/group$) were randomly assigned to three groups: solvent vehicle control groupL 2 mg/kg per 2 days GA group; 4 mg/kg per 2 days GA group. The intravenous treatments were done once every other day for 14 days. After 2 weeks, the mice were killed, and the tumors were removed and measured.

Immunohistochemistry. Immunohistochemical staining was performed using UltraSensitive S-P IHC Kit (Maixin, Fuzhou, China) according to the manufacturer’s protocols. The sections were incubated with anti-CD31, anti-VEGF or anti-HIF-1α (1:100, Santa Cruz Biotechnology) at 4°C overnight. Then, sections were stained with a streptavidin-peroxidase system, the signal was visualized using diaminobenzidine substrate and counterstaining was done with hematoxylin. For quantity, the microvessel density and the levels of VEGF and HIF-1α were measured using Image-Pro Plus 6.0 (Media Cybernetics, Silver Spring, MD, USA).

Statistical analysis. All values were expressed as mean ± standard deviation (SD) from triplicate experiments performed in a parallel manner unless otherwise indicated. Data were analyzed using an unpaired, two-tailed Student’s $t$-test. The level of significance was indicated as *$P < 0.05$ and **$P < 0.01$.

Results

Effects of GA on growth of U266 cells in vitro. To determine potential cytotoxic and anti-proliferative effects of GA, U266 cells were exposed to GA at various concentrations (0.025–6.4 μM) under normoxia and hypoxia for 8 h. The results showed that treatment with GA at concentrations above 0.4 μM led to a significant dose-dependent inhibition of U266 cell growth under normoxia and hypoxia (Fig. 1). Considering low cytotoxicity, 0.2 μM GA or less were chosen in our study.

GA suppresses hypoxia-induced VEGF expression and secretion in U266 cells. We examined VEGF expression and secretion from the U266 cells under normoxia and hypoxia and the

![Fig. 2. Effect of gambogenic acid (GA) on the secretion and expression of vascular endothelial growth factor (VEGF) in U266 cells under normoxia and hypoxia. (a) U266 cells were treated by GA (0, 0.05, 0.1, and 0.2 μM) for 8 h under normoxia and hypoxia. VEGF secretion was detected by ELISA assay. Bars were the mean ± SD (n = 3). The comparisons were made relative to untreated controls, and the different levels of significance were indicated as *$P < 0.05$ and **$P < 0.01$. (b) Effect of GA on VEGF mRNA level under normoxia and hypoxia. U266 cells were treated with various concentrations of GA (0, 0.05, 0.1, and 0.2 μM) for 4 h under normoxic and hypoxic conditions. VEGF mRNA was detected by real-time polymerase chain reaction (PCR) and analyzed by the ΔΔCt method. Bars were shown as mean ± SD (n = 3) and represent VEGF/β-actin fold relative to the untreated group. The different levels of significance were indicated as *$P < 0.05$ and **$P < 0.01$. (c) Effect of GA on VEGF protein expression under normoxia and hypoxia. U266 cells were treated with various concentrations of GA (0, 0.05, 0.1, and 0.2 μM) for 4 h under normoxic and hypoxic conditions. VEGF protein expression was analyzed by western blots. (d) For quantity of (c), images were analyzed using Image J. Bars are the mean ± SD (n = 3). The comparisons were made relative to hypoxia alone group, and the different levels of significance were indicated as *$P < 0.05$ and **$P < 0.01$.](https://www.wileyonlinelibrary.com/journal/cas)
effect of GA on that. The results showed that VEGF was more secreted under hypoxia and GA decreased VEGF secretion compared to the control group under hypoxia much more significantly than under normoxia (Fig. 2a).

Real time-PCR and western blots were used to measure the expression of VEGF, the results showed hypoxia induced upregulation of VEGF mRNA (Fig. 2b) and protein (Fig. 2c, d). The increases of VEGF caused by hypoxia were dramatically inhibited by GA in a dose-dependent manner.

**GA downregulates HIF-1α expression in hypoxia.** To investigate why GA exhibited more marked effect on VEGF secretion and expression of U266 cells under hypoxia, real time-PCR, western blots and immunofluorescence were used to evaluate the expression of HIF-1α, the key regulator of hypoxia. The results showed that in both of normoxia and hypoxia, the levels of HIF-1α mRNA were unchanged with or without GA treatment on U266 cells (Fig. 3a), but compared with little expression under normoxia, hypoxic condition elicited a robust increase of HIF-1α protein level, which can be reduced by GA in a concentration-dependent manner (Fig. 3b, c). This observation was confirmed by an immunofluorescence assay in vitro that the intracellular expression of HIF-1α was relatively sparser and weaker compared to those before GA treatment (Fig. 3d). Taken together, these findings suggested that GA might downregulate HIF-1α through decreasing translation.

The PI3K/Akt/mTOR pathway involves hypoxia-induced HIF-1α protein accumulation. The PI3K/Akt/mTOR pathway is a
crucial regulator of cell proliferation and angiogenesis. It has been reported that PI3K/Akt signaling pathway may be involved in hypoxia-induced HIF-1α protein accumulation and its downstream target gene expression.\(^{(14,15)}\) To explore whether GA can inhibit hypoxia-mediated activation of PI3K/Akt/mTOR, U266 cells were treated with 0.2 μM GA for 4 h under hypoxia. Our data showed hypoxia augmented phosphorylation of Akt and mTOR in U266 cells, which were all attenuated by GA (Fig. 4a,b). Interestingly, GA did not affect the total protein levels of these kinases, suggesting that the action of GA was specific to the protein activation.

To further check the role of the PI3K/Akt/mTOR signaling pathway in the HIF-1α/VEGF cascade, U266 cells were treated respectively with 20 μM LY294002, a commonly used inhibitor of PI3K, or 20 nM rapamycin, an inhibitor of mTOR. The results showed that blocking PI3K/Akt activation by LY294002 significantly blunted the elevation of hypoxia-induced HIF-1α and VEGF via suppressing p-Akt and p-mTOR protein levels, and inhibiting mTOR activation by rapamycin had the same effect excepting unchanged p-Akt protein level (Fig. 4c,d). Correspondingly, the increases of VEGF mRNA caused by hypoxia were dramatically inhibited after blocking PI3K/Akt/mTOR pathway, while the levels of HIF-1α mRNA were unchanged (Fig. 4e), suggesting that blocking PI3K/Akt/mTOR pathway might downregulate HIF-1α through decreasing translation. In view of these facts, our results indicated that GA decreased the hypoxia-induced HIF-1α/VEGF protein levels in U266 cells by downregulation of PI3K/Akt/mTOR pathway.

**GA inhibits the growth of transplantable tumors.** Tumor xenografts transplanted by U266 cells were used to evaluate the anti-tumor effect of GA in BALB/c nude mice in vivo. After 14-day treatments, the tumors were moved and photographed (Fig. 5a). The average tumor size of control group was \(615.5 ± 69.8\ mm^3\) while those of GA treated group were \(323.3 ± 53.5\ mm^3\) (2 mg/kg per 2 days) and \(163.3 ± 30.1\ mm^3\) (4 mg/kg per day), and the average tumor volume of rapamycin treated group was \(163.3 ± 30.1\ mm^3\). After 14 days, the tumors were isolated and weighed (Fig. 5b, c, d). The tumor weight of the control group was \(30.1 ± 6.3\ mg\). The weight of the GA treated group was \(11.3 ± 2.1\ mg\) for 2 mg/kg per 2 days, and \(16.3 ± 3.2\ mg\) for 4 mg/kg per 2 days, and the weight of the rapamycin treated group was \(16.3 ± 3.2\ mg\) (20 nM). The results showed that blocking PI3K/Akt/mTOR pathway as analyzed by western blots and real-time polymerase chain reaction (PCR) suppressed the growth of tumor xenografts. The tumor volumes of control group were \(53.5 ± 9.8\ mm^3\), \(117.5 ± 21.1\ mm^3\), and \(163.3 ± 30.1\ mm^3\) for 2 mg/kg per 2 days, 4 mg/kg per 2 days, and 20 nM rapamycin, respectively. The tumor volumes of GA treated group were \(30.1 ± 6.3\ mm^3\), \(11.3 ± 2.1\ mm^3\), and \(16.3 ± 3.2\ mm^3\) for 2 mg/kg per 2 days, 4 mg/kg per 2 days, and 20 nM rapamycin, respectively (Fig. 5b, c, d).

**GA inhibits angiogenesis of transplantable tumors.** After 14 days of treatment, the xenografts transplanted by U266 cells were used to evaluate the anti-angiogenic effect of GA in BALB/c nude mice in vivo. After 14 days, blood vessels of tumors in control group were dense and highly organized, while those in GA treated group were sparse and disorganized (Fig. 5e, f). The blood vessels of control group were \(36 ± 6\ mm\), while those of GA treated group were \(11 ± 2\ mm\) for 2 mg/kg per 2 days, and \(16 ± 3\ mm\) for 4 mg/kg per 2 days (Fig. 5e, f). The results showed that blocking PI3K/Akt/mTOR pathway as analyzed by western blots and real-time polymerase chain reaction (PCR) suppressed the growth of tumor xenografts.
GA suppresses hypoxia-induced HIF-1α in MM

HIF-1α is also hypoxic in MM patients. The HIF-1α protein is even more constitutively expressed and activated in bone marrow endothelial cells of 45% of MM relapsed patients. The hypoxic myeloma cells can induce the secretion of cytokines and growth factors, including interleukin-6, VEGF, insulin-like growth factor 1, members of the superfamily of tumor necrosis factor, transforming growth factor β1, and interleukin-10. Previous studies have shown that selective HIF-1α inhibition can block angiogenesis by suppressing the production of angiogenic cytokines, resulting in a potent anti-MM effect. Here, our results suggested that the U266 cells augmented the HIF-1α protein accumulation, and the expression and secretion of VEGF under hypoxia. Therefore, HIF-1α may be a logical target to control MM cell-derived angiogenesis.

As a promising anti-cancer agent with multiple protein targets, GA mediates a wide variety of functional antitumor effects including the induction of cell apoptosis, inhibition of proliferation and prevention of cancer metastasis and angiogenesis.

In this experiment, we demonstrated that GA dramatically inhibited the expression of HIF-1α protein in a dose-dependent manner in U266 cells under hypoxia, but did not affect HIF-1α at the mRNA level, suggesting the suppression of HIF-1α expression by GA through decreased protein translation. Furthermore, there was no obvious change in the cell viability of U266 after treatment with GA (0.05–0.2 μM) in the presence of hypoxia, showing that the effect of GA was not due to cytotoxicity.

Hypoxia is a potent inducer of HIF-1α and VEGF expression, and this induction can be augmented by PI3K/Akt activation. Previous studies have proposed that hypoxia can initiate a PI3K/Akt signaling cascade through ligand-independent activation of growth factor receptors. In patients with colorectal cancer and mantle cell lymphoma, hypoxia-induced HIF-1α protein accumulation is also in close interaction with an active PI3K/Akt/mTOR pathway. In addition, the PI3K inhibitor, LY294002, can significantly blunt HIF-1α induction under both hypoxia and the hypoxia mimetic CoCl2 in glioblastoma cells and attenuate VEGF mRNA expression. In some other studies, the mTOR kinase inhibitor impairs production of HIF-1α in kidney tumor cell lines under hypoxic condition. Moreover, rapamycin treatment effectively blocks the HIF-1α activation in gastric cancer cell lines under hypoxia and reduced the size of the CD-31-positive vessel area, leading to decreased tumor growth in a subcutaneous implantation model. In our study, hypoxic conditions can also induce activation of PI3K/Akt/mTOR pathway in U266 cells. Furthermore, treatment with LY294002, a specific inhibitor of PI3K/Akt, or rapamycin, a specific inhibitor of
mTOR, inhibited hypoxia-stimulated expression of HIF-1α; however, the levels of HIF-1α mRNA were unchanged. These results support the notion that PI3K/Akt/mTOR pathway is important for hypoxia mediated HIF-1α protein synthesis.

In order to assess whether inhibition of HIF-1α by GA in hypoxia is involved in PI3K/Akt/mTOR pathway, the signaling proteins were examined in the presence or absence of GA in hypoxic U266 cells, suggesting that inhibition of PI3K/Akt/mTOR signaling pathway may, at least partly, contribute to the attenuated effect of GA on HIF-1α expression. The inhibition of HIF-1 activity involves HIF-1 mRNA expression, HIF-1 protein translation, HIF-1 protein degradation. In our study, The suppression of HIF-1α expression by GA was due to decreased translation. The question arises whether GA might be effective on protein degradation pathways that have been tried to date.

A xenograft myeloma tumor model in nude mice was generated by subcutaneous inoculation of U266 cells to evaluate the anti-tumor and anti-angiogenesis activity of GA in vivo. As expected, consecutive administration of GA for 14 days significantly reduced the tumor size and tumor vascularization evidenced by decreased CD31 expression in tumors. Furthermore, accompanied by reduced vascular density, immunohistochemical staining of the sections revealed decrease of HIF-1α and VEGF protein, which was consistent with the findings in vitro. These results demonstrate that GA can prevent the development of intratumoral hypoxia that may be attributed to inhibition of tumor angiogenesis and growth, possibly by attenuating HIF-1α and VEGF expression inside the tumors.

In summary, we conclude that GA downregulates HIF-1α protein levels of U266 cells in hypoxia. The inhibition of HIF-1α/VEGF protein expression is associated with the suppression of PI3K/Akt/mTOR pathway, suggesting that GA may suppress human multiple myeloma progression and angiogenesis. Taken together, these results not only provide a novel mechanism to explain the antiangiogenic and anticancer effects of GA, but also imply that GA might be a new potential drug for human multiple myeloma therapy.

Disclosure Statement
The authors have no conflict of interest.

References
1 Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011; 364: 1046–60.
2 Ferlay J, Shin HR, Bray F et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893–917.
3 Vacca A, Ria R, Reale A et al. Angiogenesis in multiple myeloma. Chem Immunol Allergy 2014; 99: 180–96.
4 Bhutani M, Turkbye B, Tan E et al. Bone marrow angiogenesis in myeloma and its precursor disease: a prospective clinical trial. Leukemia 2014; 28: 413–6.
5 Sato Y. Persistent vascular normalization as an alternative goal of anti-angiogenic cancer therapy. Cancer Sci 2011; 102: 1253–6.
6 Hidematsu T, Mitsiades C, Tonom G et al. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007; 7: 585–98.
7 Martin SK, Diamond P, Grontos S et al. The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma. Leukemia 2011; 25: 1533–42.
8 Huang J, Yao X, Zhang J et al. Hypoxia-induced downregulation of mif-30c promotes epithelial-mesenchymal transition in human renal cell carcinoma. Cancer Sci 2013; 104: 1609–17.
9 Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010; 29: 625–34.
10 Colla S, Storti P, Donofrio G et al. Low bone marrow oxygen tension and hypoxia-inducible factor-1alpha overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138(+) cells. Leukemia 2010; 24: 1967–70.
11 Azab AK, Hu J, Quang P et al. Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. Blood 2012; 119: 5782–94.
12 Keith B, Johnson RS, Simon MC. HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 2012; 12: 9–22.
13 Dai T, Zheng H, Fu GS. Hypoxia confers protection against apoptosis via the PI3K/Akt pathway in endothelial progenitor cells. Acta Pharmacol Sin 2008; 29: 1245–31.
14 Hong SW, Jung KH, Lee HS et al. SB365 inhibits angiogenesis and induces apoptosis of hepatocellular carcinoma through modulation of PI3K/Akt/mTOR signaling pathway. Cancer Sci 2012; 103: 1929–37.
15 Mirzoeva S, Kim ND, Chiu K et al. Inhibition of HIF-1 alpha and VEGF expression by the chemopreventive bioflavonoid apigenin is accompanied by Akt inhibition in human prostate carcinoma PC3-M cells. Mol Carcinog 2008; 47: 686–700.
16 Kim DH, Hossain MA, Kim MY et al. A novel resveratrol analogue, HS-1793, inhibits hypoxia-induced HIF-1alpha and VEGF expression, and migration in human prostate cancer cells. Int J Oncol 2013; 43: 1915–24.
17 Zhong H, Chiles K, Feldser D et al. Modulation of hypoxia-inducible factor 1 alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 2000; 60: 1541–5.
18 Karar J, Cerniglia GJ, Lindsten T et al. Dual PI3K/mTOR inhibitor NVP-BEZ235 suppresses hypoxia-inducible factor (HIF)-1alpha expression by blocking protein translation and increases cell death under hypoxia. Cancer Biol Ther 2012; 13: 1102–11.
19 Yang LJ, Chen Y. New targets for the antitumor activity of gambogic acid in hematologic malignancies. Acta Pharmacol Sin 2013; 34: 191–8.
20 Lu N, Hui H, Yang H et al. Gambogic acid inhibits angiogenesis through inhibiting PHD2-VHL-HIF-1alpha pathway. Eur J Pharm Sci 2013; 49: 220–6.
21 Zhang W, Chen BA, Jin JF et al. Involvement of c-Jun N-terminal kinase in reversal of multidrug resistance of human leukemia cells in hypoxia by 5-bromotetrandrine. Leuk Lymphoma 2013; 54: 2506–16.
22 Ghosh AK, Shanafelt TD, Cimmino A et al. aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cells. Blood 2009; 113: 5568–74.
23 Minoia C, Quero C, Asselti M et al. Changes in angiogenesis and hypoxia-inducible factor-1alpha protein expression in relapsed/refractory indolent non-Hodgkin lymphomas. Br J Haematol 2013; 163: 640–5.
24 Passam FH, Alexandrakis MG, Kafousi M et al. Histological expression of angiogenic factors: VEGF, PDGFR alpha, and HIF-1alpha in Hodgkin lymphoma. Pathol Res Pract 2009; 205: 11–20.
25 Bhaskar A, Gupta R, Vishnubhatla S et al. Angiopoietins as biomarker of disease activity and response to therapy in multiple myeloma. Leuk Lymphoma 2013; 54: 1473–8.
26 Ria R, Catacchio I, Berardi S et al. HIF-1 alpha of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic target. Clin Cancer Res 2014; 20: 847–58.
27 Storti P, Bolzoni M, Donofrio G et al. Hypoxia-inducible factor (HIF)-1 alpha suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction. Leukemia 2013; 27: 1697–706.
28 Wang X, Chen W. Gambogic acid is a novel anti-cancer agent that inhibits cell proliferation, angiogenesis and metastasis. Anticancer Agents Med Chem 2012; 12: 994–1000.
29 Wang Y, Xiang W, Wang M et al. Methyl jasmonate sensitizes human bladder cancer cells to gambogic acid-induced apoptosis through down-regulation of EZH2 expression by miR-101. Br J Pharmacol 2014; 171: 618–35.
30 Mazure NM, Chen EY, Laderoute KR et al. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood 1997; 90: 3322–31.
31 Chen EY, Mazure NM, Cooper JA et al. Hypoxia activates a platelet-derived growth factor receptor/phosphatidylinositol 3-kinase/Akt pathway that results in glycogen synthase kinase-3 inactivation. Cancer Res 2001; 61: 2429–33.
32 Argyriou P, Papageorgiou SG, Panteleoun V et al. Hypoxia-inducible factors in mantle cell lymphoma: implication for an activated mTORC1→HIF-1alpha pathway. Ann Hematol 2011; 90: 315–22.
33 Greijer AE, Delis-Van Diemen PM, Fijneman RJ et al. Presence of HIF-1 and related genes in normal mucosa, adenomas and carcinomas of the colorectum. Virchows Arch 2008; 452: 535–44.
34 Pore N, Jiang Z, Shu HK et al. Akt1 activation can augment hypoxia-inducible factor-1 alpha expression by increasing protein translation through a mammalian target of rapamycin-independent pathway. Mol Cancer Res 2006; 4: 471–9.
35 Thomas GV, Tran C, Mellinghoff IK et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 2012; 18: 122–7.
36 Lang SA, Gaumann A, Koehl GE et al. Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Int J Cancer 2007; 120: 1803–10.